Last updated: August 27, 2026
Biogen International GmbH v. Banner Life Sciences LLC concerned Banner's Paragraph IV challenge to Biogen's Tecfidera patents covering dimethyl fumarate delayed-release capsules for multiple sclerosis. The case was part of the broader U.S. generic-drug litigation over Tecfidera. Its commercial significance declined after the Federal Circuit affirmed invalidity of Biogen's key Tecfidera composition patent in parallel litigation involving Mylan. [1][2]
What drug and patents were involved in Biogen v. Banner?
The dispute involved Tecfidera, whose active ingredient is dimethyl fumarate, or DMF. Tecfidera is approved as delayed-release capsules in 120-mg and 240-mg strengths for relapsing forms of multiple sclerosis. Biogen's principal asserted patent was U.S. Patent No. 7,619,001, commonly called the '001 patent. [3]
| Item |
Detail |
| Brand drug |
Tecfidera |
| Active ingredient |
Dimethyl fumarate |
| Dosage form |
Delayed-release oral capsules |
| Approved strengths |
120 mg and 240 mg |
| Innovator |
Biogen |
| Primary patent |
U.S. Patent No. 7,619,001 |
| Patent title |
Pharmaceutical compositions comprising dimethyl fumarate |
| Case number |
1:18-cv-02054 |
| Court |
U.S. District Court for the District of Delaware |
| Defendant |
Banner Life Sciences LLC |
| Statutory basis |
Hatch-Waxman Paragraph IV litigation |
The '001 patent claimed pharmaceutical compositions containing dimethyl fumarate and related components. Biogen listed it in the FDA Orange Book for Tecfidera. The patent's Orange Book expiration date was June 1, 2028, subject to applicable patent-term adjustments and extensions. [3]
Why did Biogen sue Banner Life Sciences?
Banner submitted an abbreviated new drug application, or ANDA, seeking FDA approval for generic dimethyl fumarate delayed-release capsules. Banner certified under Paragraph IV that the listed Tecfidera patent was invalid, unenforceable, or would not be infringed by the proposed generic product.
Biogen treated Banner's certification as an act of infringement under 35 U.S.C. § 271(e)(2). The action was filed in the District of Delaware in November 2018, within the 45-day period following Biogen's receipt of Banner's Paragraph IV notice. [4]
The filing triggered the Hatch-Waxman 30-month stay that generally prevents FDA approval of the ANDA while the patent case is pending, unless the court enters an earlier judgment or the parties resolve the dispute.
What claims did Biogen assert against Banner?
Biogen's case focused on the '001 patent and the composition of Banner's proposed generic product. The central issues were:
- Whether Banner's delayed-release capsules met the limitations of the asserted composition claims.
- Whether the '001 patent was invalid for obviousness.
- Whether the patent satisfied the written-description requirement.
- Whether claim construction limited the scope of the claimed DMF formulation.
- Whether the proposed ANDA product created a statutory basis for infringement.
The case was closely related to Biogen's parallel lawsuits against Mylan and other generic-drug manufacturers. Because the same Tecfidera patent was attacked on substantially similar grounds, rulings in the parallel actions affected the economic value of the Banner litigation.
How did the Federal Circuit affect the Banner case?
The Federal Circuit addressed the Tecfidera patent in Biogen International GmbH v. Mylan Pharmaceuticals Inc. The court affirmed the district court's determination that the asserted '001 patent claims were invalid for obviousness. [2]
The Federal Circuit held that the prior art, including earlier fumarate products and clinical information concerning multiple sclerosis treatment, supplied a reason to develop a DMF treatment with the claimed dosage characteristics. The court also concluded that the asserted claims did not reflect a sufficient nonobvious technical advance over the prior art.
That ruling materially weakened Biogen's position in the Banner case. Once the same patent was held invalid in the parallel Mylan litigation, Biogen faced a substantially reduced basis for maintaining infringement claims against Banner. The decision also removed the principal patent barrier to FDA approval and commercial entry by generic DMF manufacturers.
Was the Tecfidera patent invalidated for obviousness?
Yes. The Federal Circuit affirmed invalidity of the asserted '001 patent claims for obviousness in the parallel Mylan appeal. [2]
The Federal Circuit's analysis rejected the argument that the claimed DMF dosage regimen was sufficiently inventive because of reported tolerability and efficacy benefits. The court treated the prior art as providing a reasonable expectation that DMF could be used to treat multiple sclerosis and that the claimed dosage range could be identified through routine clinical development.
The decision was important because the '001 patent had been the principal Orange Book barrier for Tecfidera delayed-release capsules. The patent's formal expiration date was later than the expected commercial entry date, but the invalidity judgment effectively removed that barrier before expiration.
What was the litigation status of Biogen v. Banner?
The Banner action is closed. The case did not produce a durable final injunction protecting the '001 patent against Banner's generic product. The patent's invalidity in parallel litigation eliminated the commercial value of continuing to pursue the same composition patent as the principal basis for blocking Banner's ANDA.
The public litigation record should be read together with Biogen's other Tecfidera cases. A dismissal or termination of the Banner action does not necessarily establish that Banner prevailed on every pleaded defense. It means that the case ceased to function as an active patent obstacle to generic entry.
Did Biogen and Banner enter a settlement agreement?
A publicly reported settlement with a fully disclosed generic-entry date is not the principal event determining the outcome of the Banner litigation. The key legal event was the invalidity ruling against the '001 patent in the parallel Mylan case.
Any private settlement terms, licensing rights, authorized-generic arrangements, supply commitments, or launch provisions should not be inferred from the docket absent an unsealed settlement document or a definitive public disclosure. The enforceability and commercial impact of any confidential agreement would depend on its terms and on FDA approval status.
What was the Orange Book status of Tecfidera?
Tecfidera's Orange Book listing included U.S. Patent No. 7,619,001. The patent covered the DMF delayed-release composition used in the approved product. [3]
Orange Book and exclusivity timeline
| Event |
Date or period |
| Tecfidera FDA approval |
March 27, 2013 |
| New chemical entity exclusivity |
Expired in 2018 |
| Banner Paragraph IV litigation |
Filed in 2018 |
| '001 patent Orange Book expiration |
June 1, 2028 |
| Federal Circuit invalidity ruling in Mylan litigation |
2021 |
| Generic DMF entry environment |
Opened after invalidity and regulatory approval events |
Tecfidera received five years of new chemical entity exclusivity, followed by three years of additional regulatory exclusivity for the approved clinical indication. Those exclusivity periods expired before the listed patent date. The principal remaining protection was patent-based rather than FDA exclusivity-based. [3][5]
When did Tecfidera lose exclusivity?
Tecfidera lost its key regulatory exclusivity in 2018, when its five-year new chemical entity exclusivity and associated market protection no longer prevented ANDA approval based solely on regulatory exclusivity.
Patent protection nominally extended to 2028 through the '001 patent. The effective loss of patent exclusivity occurred earlier when the patent was held invalid for obviousness. Generic approval and launch timing then depended on FDA review, ANDA status, court orders, and any private commercial arrangements.
What generic entry risks existed for Banner?
Banner's principal entry risks were legal and regulatory rather than technical.
Legal risks
- The District of Delaware could have found infringement if the ANDA product met the asserted claim limitations.
- Biogen could have obtained an injunction during the patent term.
- Claim construction could have expanded the scope of the asserted claims.
- A favorable ruling for Biogen could have preserved the 30-month stay and delayed FDA approval.
Regulatory risks
- FDA approval depended on completion of ANDA review.
- Labeling had to remain within the scope of the reference listed drug.
- Bioequivalence and delayed-release performance had to satisfy FDA requirements.
- Manufacturing-site and quality-system issues could delay approval independently of patent litigation.
Commercial risks
- Multiple generic applicants could enter simultaneously.
- Price erosion could be rapid after approval.
- Biogen could respond with contracting, rebates, patient-support programs, or an authorized generic.
- Dimethyl fumarate demand could shift among generic manufacturers based on formulary access and supply reliability.
The invalidity result reduced the first category of risk and left regulatory execution and market competition as the principal barriers.
Were formulation patents important in this litigation?
Yes. Tecfidera's protection depended heavily on formulation and composition claims rather than on broad ownership of dimethyl fumarate as a chemical compound. DMF was known before Tecfidera, and the competitive dispute centered on the use of DMF in a particular pharmaceutical product and dosage presentation.
A formulation patent can have substantial commercial value even when the active ingredient is old. Its practical strength depends on claim breadth, written-description support, obviousness defenses, the ability to prove ANDA infringement, and whether the patent is listed in the Orange Book.
In this case, the formulation patent's value was sharply reduced by the obviousness ruling. The decision illustrates the vulnerability of pharmaceutical composition claims where the active ingredient, therapeutic use, and relevant dosage concepts are disclosed across multiple prior-art references.
Did method-of-use patents or biosimilar issues affect Banner?
Method-of-use patent issues were not the primary driver of the Banner litigation. The case concerned a small-molecule generic ANDA, not a biologic and not a biosimilar application under the Public Health Service Act.
Biosimilar risk therefore was not applicable. The relevant pathway was the Hatch-Waxman ANDA process, with Paragraph IV certification against an Orange Book-listed patent.
Biogen could still have pursued method-of-use patents in other Tecfidera litigation, but those patents would have raised separate questions involving label carve-outs, induced infringement, and the precise scope of the approved indication.
How strong was Biogen's Tecfidera patent estate?
Biogen's Tecfidera estate had meaningful initial commercial strength because:
- the '001 patent was listed in the Orange Book;
- the patent term extended beyond the period of FDA regulatory exclusivity;
- generic manufacturers had to address the patent through Paragraph IV litigation;
- the patent covered a commercially important delayed-release composition.
Its legal strength was weaker after the obviousness ruling. The main weakness was that the claimed formulation and dosage parameters could be reconstructed from known DMF pharmacology, earlier fumarate products, clinical disclosures, and routine optimization. [2]
The estate's commercial durability also depended on secondary patents, regulatory exclusivity, manufacturing controls, and market tactics. Those protections could slow erosion but could not restore an invalidated primary composition patent.
What revenue exposure did Biogen face?
Tecfidera was one of Biogen's largest products before generic entry. FDA approval records and Biogen's public financial filings establish the product's strategic importance, while generic competition created direct exposure to price erosion and prescription migration. [3][6]
The principal revenue risks were:
| Risk |
Effect on Biogen |
| Generic DMF approval |
Reduced net price and market share |
| Multiple simultaneous entrants |
Faster price erosion |
| Formulary substitution |
Lower branded prescription volume |
| Authorized generic strategy |
Potentially preserves volume but reduces price |
| Patient switching |
Weakens brand retention |
| Secondary patent challenges |
Limits ability to extend exclusivity |
Biogen's remaining defenses included brand loyalty, physician familiarity, patient-support programs, contracting, and any surviving patent or regulatory rights. None provided the same blocking power as a valid Orange Book-listed composition patent.
Key Takeaways
- Biogen sued Banner in the District of Delaware after Banner filed a Paragraph IV ANDA for generic dimethyl fumarate delayed-release capsules.
- The central patent was U.S. Patent No. 7,619,001, listed for Tecfidera and carrying an Orange Book expiration date of June 1, 2028.
- The Federal Circuit affirmed invalidity of the '001 patent for obviousness in parallel litigation involving Mylan.
- That ruling substantially weakened Biogen's case against Banner and removed the principal patent barrier to generic DMF entry.
- The dispute involved a small-molecule ANDA, not a biosimilar application.
- Tecfidera's regulatory exclusivity had expired before the patent invalidity ruling.
- Commercial risk shifted from patent blocking to FDA approval, generic competition, formulary access, and price erosion.
FAQs About Biogen v. Banner Life Sciences
What was Banner's generic product?
Banner sought approval for generic dimethyl fumarate delayed-release capsules corresponding to Tecfidera's 120-mg and 240-mg strengths.
What patent did Biogen assert against Banner?
Biogen principally asserted U.S. Patent No. 7,619,001, directed to pharmaceutical compositions comprising dimethyl fumarate.
Did Banner's case involve Tecfidera's active ingredient?
Yes. The litigation concerned dimethyl fumarate, the active ingredient in Tecfidera.
Could Biogen block generic Tecfidera after the '001 patent ruling?
The invalidity ruling materially reduced Biogen's ability to use the '001 patent to block generic entry. Other patents, regulatory rights, or private agreements would require separate analysis.
Was Banner the only company challenging Tecfidera?
No. Mylan and other generic applicants also challenged Biogen's Tecfidera patent estate. The Mylan litigation produced the Federal Circuit ruling that affirmed invalidity of the '001 patent claims.
References
- Biogen International GmbH v. Banner Life Sciences LLC, No. 1:18-cv-02054, U.S. District Court for the District of Delaware, docket record.
- Biogen International GmbH v. Mylan Pharmaceuticals Inc., 18-1161, 18-1231, U.S. Court of Appeals for the Federal Circuit (2021).
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Tecfidera dimethyl fumarate delayed-release capsules.
- Drug Price Competition and Patent Term Restoration Act of 1984, 21 U.S.C. § 355(j); 35 U.S.C. § 271(e)(2).
- U.S. Food and Drug Administration. (2024). New drug application exclusivity and patent information for Tecfidera.
- Biogen Inc. (2021). Annual report on Form 10-K. U.S. Securities and Exchange Commission.
